Key Drivers
- Large cash runway
- Zero revenue
- Heavy cash burn
AIAI Summary
Alto's $120M PIPE and completed Phase‑2 enrollment shift the investment thesis from “will they survive?” to “will ALTO‑101's upcoming POC and biomarker validation justify a growth multiple,” making the mid‑term readout the pivotal value inflection. Monitor the ALTO‑101 data, incremental R&D allocation across programs, and partnership interest closely, because a negative readout or need for fresh equity before de‑risking would likely trigger a sharp re‑rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Large cash runway
- •Zero revenue
- •Heavy cash burn
ANRO has a strong balance sheet with ~$177M cash and low leverage but no revenue, steep operating losses and heavy cash burn funded by external financing.
Price Behavior
Key Price Behavior Insights:
- •Above last month MA
- •Higher swing lows
- •Resistance capped
Price action is mildly bullish: price sits above the last month simple moving average with RSI ~61 and higher swing lows, but upside is capped at $22.40–$22.60 and failure to reclaim $22.5–$24.3 or a break below ~$20 would flip the near-term bias.
Strong intramonth spike to $24.29 then pullback into $21 by 2026-03-20
Sentiment & News
Key News Insights:
- •$120M PIPE
- •Investor outreach
- •FY2025 update
Alto Neuroscience raised $120M via a PIPE while rolling out FY2025 results and coordinated investor presentations, signaling improved runway and amplified investor visibility as clinical programs advance.
The financing and heightened engagement should bolster runway and market confidence, helping stabilize the stock ahead of upcoming clinical catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings